Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University have entered into a new research collaboration applying RuiYi's iCAPS (Intermembranous Antigen Presenting System) technology to develop new monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to investigate the biological function and structure of GPCRs.
Subscribe to our email newsletter
The iCAPS platform can isolate and present functional GPCRs in their correct confirmation to identify selective monoclonal antibody inhibitors or activators with great specificity for more effective therapeutics.
RuiYi scientific founder and iHuman Institute founding director of Ray Stevens said as mediators of cellular communication, GPCRs and their related intracellular proteins play a central role in human biology and are important targets in mediating physiological processes to treat disease.
"The evolution and power of RuiYi’s iCAPS technology enables the generation of antibodies to GPCRs with great selectivity, which can be used not only for antibody therapeutic development but also for probing the structure, function, chemical probe discovery, and signaling pathways of GPCRs," Stevens said.
In 2012, Dr. Stevens founded the iHuman Institute to focus on human cell signaling research.
RuiYi president and CEO Paul Grayson said bringing iCAPS technology to iHuman Institute will synergize research efforts in elucidating GPCR structure-function and how structure affects the physiological function.
"The knowledge gained from this collaboration will not only advance the scientific understanding of human cell signaling but also help us better identify selective antibody inhibitors or activators for more effective therapeutics," Grayson said.